Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma
British Journal of Haematology · 2026-09 · 209 (3) · 1101-1110
DOI: 10.1111/bjh.70704 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.07.2026. Verfasst von Jiapei Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Specialized Diseases Clinical Research Fund of Jiangsu Province Hospital.
Abstract (Originalsprache)
While minimal residual disease (MRD) is a well‐recognized prognostic marker in multiple myeloma (MM), the clinical significance of dynamic MRD trajectories and MRD‐driven therapies remains incompletely elucidated. This retrospective study analysed serial MRD results from 231 newly diagnosed multiple myeloma (NDMM) patients who achieved ≥ complete remission (CR). MRD negativity independently predicted superior progression‐free survival (PFS) (hazard ratio [HR] = 0.222; 95% confidence interval [CI] 0.124–0.400, p < 0.001) and overall survival (OS) (HR = 0.280; 95% CI 0.097–0.809, p = 0.019). Sustaining MRD negativity for ≥6 months improved OS ( p < 0.001), while negativity duration ≥12 months conferred dual prognostic benefits for both PFS and OS (both p < 0.001). Patients with late MRD conversion (after ≥12 months of negativity) had OS comparable to those with sustained negativity ( p = 0.339). Elevated circulating plasma cell at diagnosis (HR = 3.761; 95% CI 1.225–11.550, p = 0.021), failure to achieve MRD negativity post‐induction (HR = 2.886; 95% CI 1.065–7.819, p = 0.037), and a high abnormal PC/BMPC% at MRD conversion (HR = 4.091; 95% CI 1.429–11.701, p = 0.009) were independent risk factors for progression post‐conversion. These findings demonstrate the prognostic significance of sustained MRD negativity and support serial MRD monitoring as a potential basis for individualized MRD‐driven treatment strategies in NDMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
ORCID-Profile: Yuanyuan Jin, Xuxing Shen, Lijuan Chen
Förderung
- National Natural Science Foundation of China
- Specialized Diseases Clinical Research Fund of Jiangsu Province Hospital
Zitieren
APA
Yu, J., Chen, Q., Shi, M., Liu, L., Jin, Y., Shen, X., Tian, T., Wu, Y., & Chen, L. (2026). Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma. British Journal of Haematology, 209(3), 1101-1110. https://doi.org/10.1111/bjh.70704
Vancouver
Yu J, Chen Q, Shi M, Liu L, Jin Y, Shen X, et al. Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma. British Journal of Haematology. 2026;209(3):1101-1110. doi:10.1111/bjh.70704
BibTeX
@article{Yu2026,
author = {Yu, Jiapei and Chen, Qi and Shi, Min and Liu, Lu and Jin, Yuanyuan and Shen, Xuxing and Tian, Tian and Wu, Yujie and Chen, Lijuan},
title = {Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {3},
pages = {1101--1110},
doi = {10.1111/bjh.70704}
}
EUVIMED